Health & science
Drug Formulary Review One-Pager
Compare drugs on cost and results before a contract. Pharmacy committees use it to decide.
Make one freeFree, no account needed
What’s on It
- TableWhat We Spent on Four Agents Last Year
- Donut chart of the mixWhere the $7.67M Went
- Headline numbersSame Indication, Two Prices
- Checklist of next stepsWhat Has to Be True Before We Switch
Sample One-Pager. Company and figures are made up.
Formulary Review: Biologics
Calder Ridge Medical Center · Pharmacy & Therapeutics Committee · FY27 contract cycle
What We Spent on Four Agents Last Year
| Agent | Cost per patient / yr | Patients | FY26 spend |
|---|---|---|---|
| Velmarin | $26,400 | 118 | $3.12M |
| Anturex | $31,900 | 74 | $2.36M |
| Kesibra | $18,700 | 96 | $1.80M |
| Doravel (biosimilar) | $9,850 | 41 | $0.40M |
Where the $7.67M Went
Velmarin41%
Anturex31%
Kesibra23%
Doravel5%
Same Indication, Two Prices
Velmarin per patient
$26,400
Doravel per patient
$9,850
What Has to Be True Before We Switch
Clinical review signed off by the therapeutics group
Supplier pricing held firm through the FY27 cycle
Order sets and infusion pump libraries rebuilt
Notice served to the 34 prescribers affected
Patient letters drafted for the 118 on Velmarin
Make One from Your File
Drop in a PDF, Word or PowerPoint file. Get your One-Pager in a minute or two.
Make one free